CenterWell Pharmacy, Inc. is a wholly owned subsidiary of Humana Inc. (NYSE: HUM), the Louisville, Kentucky–based health insurer and care-delivery company. It was formed by rebranding Humana Pharmacy and Humana Specialty Pharmacy under the CenterWell name, a change announced June 13, 2022. CenterWell is Humana's healthcare services organization; a 2026 company statement puts CenterWell at more than 34,000 employees nationwide, though that figure covers primary care, home health and pharmacy together, not CenterWell Pharmacy alone. Humana's consolidated revenue was roughly $117 billion for 2024, per its SEC filings, so no separate revenue figure for the pharmacy entity is public.
Operations. CenterWell Pharmacy is a mail-order and specialty pharmacy business. Offerings include prescription home delivery, specialty medication dispensing and support (CenterWell Specialty Pharmacy), over-the-counter fulfillment, and retail pharmacies located inside Humana-owned primary care locations. Humana's investor materials state that CenterWell Pharmacy served nearly 2.5 million customers for home delivery and specialty needs and reported mail-order penetration above 30% of individual Medicare Advantage members. It also contracts for third-party, payer-agnostic fulfillment, including direct-to-consumer and direct-to-employer arrangements. A 162,000-square-foot mail-order distribution center opened in Orlando, Florida, in 2026.
Litigation posture. All five tracked matters are plaintiff-side filings, zero as defendant. CenterWell is an operating company using the courts offensively as a direct purchaser of pharmaceuticals, not a non-practicing entity or shell licensor asserting an acquired patent portfolio. The suits cluster in the Southern District of New York, not a notoriously plaintiff-friendly patent venue such as the Eastern District of Texas.
Notable cases. The tracked cases are all variations of CenterWell Pharmacy, Inc. v. Celgene Corp. et al., filed September 13, 2024 (S.D.N.Y. 1:24-cv-06924). The complaint alleges antitrust violations under 15 U.S.C. § 2 against Celgene and Bristol Myers Squibb over pomalidomide (brand name Pomalyst), including Walker Process fraud allegations concerning patents such as 8,828,427, 9,993,467, 10,555,939, 8,198,262, 8,673,939 and 8,735,428, plus alleged reverse-payment settlements with generic manufacturers. The case was consolidated with Louisiana Health Service & Indemnity Co. et al. v. Celgene Corp. et al. (1:23-cv-07871) before Judge Edgardo Ramos.